Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GRAP
REST API REST API
Homo sapiens
GRAP is differentially expressed in 180 experiments: 79 organism parts: spleen, kidney, ... (77 more);, 154 disease states: normal, acute myeloid leukemia, ... (152 more);, 51 cell types 259 cell lines 14 compound treatments and 67 other conditions.
Orthologs zgc:109892 (Danio rerio)   grap (Danio rerio)   ENSGALG00000005094 (Gallus gallus)   grap (Xenopus laevis)   GRAP (Canis familiaris)   (Compare orthologs)
InterPro Term SH2, SH3_domain, SH3_2, p67phox
Gene Ontology Term protein binding, cytoplasm, cell-cell signaling, Ras protein signal transduction, SH3/SH2 adaptor activity
UniProt Accession Q13588, A8MW78
Search EB-eye ENSG00000154016
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-22541, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-1880, E-GEOD-22152, E-MEXP-1006, E-GEOD-22639, E-GEOD-18005, ... (23 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
MCF-10A
2
E-GEOD-14990, E-TABM-420
GM13811
1
E-TABM-321
KHOS240S
1
E-MTAB-37
BC3
1
E-MTAB-37
Y79
1
E-MTAB-37
253 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-20677, E-GEOD-13909, ... (26 experiments)

Factor Value U/D Experiments
centrocyte
2
E-TABM-702, E-GEOD-15271
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD4+ T cell
1
2
5
E-AFMX-5, E-TABM-145, E-GEOD-6740
bronchial epithelial
1
E-MTAB-25
mononuclear cell
1
E-MEXP-66
immortalized cell culture
1
E-GEOD-14990
45 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-6872, E-GEOD-1869, E-MEXP-2069, ... (39 experiments)

Factor Value U/D Experiments
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
control
2
E-GEOD-8121, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
lymphoma
2
E-MTAB-37, E-MTAB-62
squamous cell carcinoma
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
1
2
E-GEOD-1729, E-MTAB-62, E-GEOD-995
148 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-3284, E-GEOD-412, E-TABM-782, E-GEOD-5824, ... (7 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-7307, E-GEOD-5824, E-GEOD-7400, E-TABM-782, E-GEOD-412 ... (5 experiments)
unknown
1
E-GEOD-7307
granulocyte-colony stimulating factor
1
E-GEOD-7400
Cxcl12
1
1
E-GEOD-7307
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
resveratrol
1
E-TABM-782
8 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138, E-GEOD-19665, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-GEOD-17385

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-321, E-GEOD-18736, E-TABM-868, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (23 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-980, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22229, E-GEOD-26495, E-GEOD-22152

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19069

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.458 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM